5/17/2023 0 Comments Project 007 strain leaflyOverall, cannabinoids were perceived to be efficacious across all genders and ages, and no significant differences were found among product forms, ingestion methods, or gender groups. Sessions were analyzed, and both descriptive statistics and linear mixed-effects modeling were completed to examine use patterns and perceived efficacy. Our analyses examined 991 medicinal cannabis users with insomnia across 24,189 tracked cannabis use sessions. We conducted a retrospective study of medicinal cannabis users to investigate the use profile and perceived efficacy of cannabinoids for the management of insomnia.ĭata were collected using the Strainprint app, which allows medicinal cannabis users to log conditions and symptoms, track cannabis use, and monitor symptom severity pre- and postcannabis use. Although insomnia is one of the main reasons individuals seek medicinal cannabis, little is known about the profile of cannabinoid use or the perceived benefit of the use of cannabinoids in daily life. Insomnia is a prevalent condition that presents itself at both the symptom and diagnostic levels. Our results could help the cannabis industry achieve better control of product consistency. Because these differences were perceptible to untrained panelists, they may also be noticed by retail consumers. It appears that within-strain genetic differences are associated with differences in aroma profile. Within a strain, aroma descriptor frequencies for the genetic outlier were frequently at odds with those of the consensus samples. Aroma profiles were obtained by 55 sniff panelists using quantitative sensory evaluation of 40 odor descriptors. A genetic outlier sample was available for all but one strain. Results were used to select 15 samples for olfactory testing. We genotyped 32 samples using variable microsatellite regions to determine a consensus strain genotype and identify genetic outliers (if any) for four strains. We asked whether genetically inconsistent samples of a commercial strain also display inconsistent aroma profiles. Yet genetic inconsistencies have been noted within named strains. Strains are often associated with phenotypic traits of interest to consumers, such as aroma and cannabinoid content. is grown and marketed under a large number of named strains. These differences have the potential to lead to phenotypic differences and unexpected effects, which could be surprising for the recreational user, but have more serious implications for patients relying on strains that alleviate specific medical symptoms.Ĭannabis sativa L. Significant genetic differences within samples of the same strain were observed indicating that consumers could be provided inconsistent products. We failed to find clear genetic support for commonly referenced Sativa, Indica and Hybrid types as described in online databases. However, after the removal of obvious outliers, many strains showed considerable genetic stability. ![]() The analyses revealed genetic inconsistencies within strains, with most strains containing at least one genetic outlier. Samples were examined to determine if there is any genetic distinction separating the commonly referenced Sativa, Indica and Hybrid types and if there is consistent genetic identity found within strain accessions obtained from different facilities.Īlthough there was strong statistical support dividing the samples into two genetic groups, the groups did not correspond to commonly reported Sativa/Hybrid/Indica types. We developed ten de-novo microsatellite markers using the "Purple Kush" genome to investigate potential genetic variation within 30 strains obtained from dispensaries in three states. ![]() In this research, we examined commercially available, drug-type Cannabis strains using genetic methods to determine if the commonly referenced distinctions are supported and if samples with the same strain name are consistent when obtained from different facilities. ![]() As Cannabis legalization and consumption increases, the need to provide consumers with consistent products becomes more pressing. Despite more than 2000 named strains being available to consumers, questions about the consistency of commercially available strains have not been investigated through scientific methodologies. As Cannabis has become legal for medical and recreational consumption in many states, consumers have been exposed to a wave of novel Cannabis products with many distinctive names. Distinctive Cannabis varieties are ostracized from registration and therefore nearly impossible to verify. Unlike other plants, Cannabis sativa is excluded from regulation by the United States Department of Agriculture (USDA).
0 Comments
Leave a Reply. |